NCCM
MDGL icon

Nine Chapters Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Nine Chapters Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-3,706
Closed -$226K – 323
2015
Q3 		$226K Buy
3,706
+2,197
+146% +$159K 0.02% 804
2015
Q2 		$118K Buy
+1,509
New +$127K 0.01% 864
2014
Q4 		– Sell
-551
Closed -$58K – 1074
2014
Q3 		$58K Buy
+551
New +$76.6K 0.01% 955

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nine Chapters Capital Management's MDGL Position: Q4 2015 in Review

Nine Chapters Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2015, closing a stake of 3,706 shares — an estimated $226K sold.

Nine Chapters Capital Management first reported a position in MDGL in Q3 2014 and held it in 3 quarters. The position peaked at $226K in Q3 2015. 75 funds tracked by Wall St. Rank hold MDGL as of Q4 2015.

  • Nine Chapters Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Nine Chapters Capital Management sold 3,706 Madrigal Pharmaceuticals shares in Q4 2015, an estimated $226K.
  • Nine Chapters Capital Management first reported a position in Madrigal Pharmaceuticals in Q3 2014 and held it in 3 quarters.
  • Nine Chapters Capital Management's Madrigal Pharmaceuticals position peaked at $226K in Q3 2015.
  • 75 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2015.

Based on Nine Chapters Capital Management's 13F filing for Q4 2015.